Selected article for: "blood cell and LYM lymphocyte"

Author: Yan, Wu; Chen, Danrong; Bigambo, Francis Manyori; Wei, Hongcheng; Wang, Xu; Xia, Yankai
Title: Differences of blood cells, lymphocyte subsets and cytokines in COVID-19 patients with different clinical stages: a network meta-analysis
  • Cord-id: q39t0u2a
  • Document date: 2021_2_8
  • ID: q39t0u2a
    Snippet: BACKGROUND: Due to the rapid spread of coronavirus disease 2019 (COVID-19) worldwide, it is necessary to ascertain essential immune inflammatory parameters that describe the severity of the disease and provide guidance for treatment. We performed network meta-analyses to determine differences in blood cells, lymphocyte subsets, and cytokines in COVID-19 patients with different clinical stages. METHODS: Databases were systematically searched to May 2, 2020, and updated on June 1, 2020. Network me
    Document: BACKGROUND: Due to the rapid spread of coronavirus disease 2019 (COVID-19) worldwide, it is necessary to ascertain essential immune inflammatory parameters that describe the severity of the disease and provide guidance for treatment. We performed network meta-analyses to determine differences in blood cells, lymphocyte subsets, and cytokines in COVID-19 patients with different clinical stages. METHODS: Databases were systematically searched to May 2, 2020, and updated on June 1, 2020. Network meta-analyses were conducted via Stata 15.0, and the mean difference (MD) and its 95% CI were used as the effect values of the pooled analysis. RESULTS: Seventy-one studies were included involving 8647 COVID-19 patients, White blood cell (WBC), neutrophil (NEUT), IL-6, and IL-10 counts increased significantly with worsening of the COVID-19, while lymphocyte (LYM) counts decreased. The levels of platelet (PLT), CD3(+), CD4(+), CD8(+), and CD19(+) cells in severe and critical patients were significantly lower than those in mild patients. IL-1β count was significantly elevated in critical patients. CONCLUSIONS: Immune suppression and inflammatory injury play crucial roles in the progression of COVID-19, and the identification of susceptible cells and cytokines provide guidance for the early and accurate treatment of COVID-19 patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-021-05847-9.

    Search related documents:
    Co phrase search for related documents
    • abstract title and additional file: 1
    • abstract title and long term research: 1
    • abstract title and low quality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute lung injury and additional file: 1, 2, 3, 4, 5
    • acute lung injury and low quality: 1, 2, 3
    • acute lung injury and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute lung injury and lung lesion: 1
    • acute lung injury and lung lymphocyte: 1
    • acute respiratory distress syndrome and additional cytokine: 1
    • acute respiratory distress syndrome and additional file: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute respiratory distress syndrome and long term research: 1, 2, 3, 4, 5, 6, 7, 8
    • acute respiratory distress syndrome and low quality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • acute respiratory distress syndrome and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory distress syndrome and lung lesion: 1, 2, 3
    • acute respiratory distress syndrome and lung lymphocyte: 1, 2
    • additional file and lung injury: 1, 2, 3, 4, 5, 6
    • additional file and lung lymphocyte: 1
    • long term research and low quality: 1, 2
    • low quality and lung injury: 1, 2, 3, 4